Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hikma Pharmaceuticals ( (GB:HIK) ) has provided an announcement.
Hikma Pharmaceuticals has published its Annual Report and Accounts for the year ended 31 December 2025, alongside the notice of its 2026 Annual General Meeting, making both documents available to shareholders online. The filings have also been submitted to the UK National Storage Mechanism, underscoring compliance with listing requirements and providing investors with formal access to the company’s latest financial and governance disclosures.
By distributing these materials, Hikma is setting the stage for shareholder engagement ahead of the AGM, where investors can review performance, strategy and governance matters. The move reinforces transparency for stakeholders and aligns the company with regulatory standards that support informed decision-making in the capital markets.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £2300.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a London-listed pharmaceutical company focused on developing, manufacturing and marketing generic and specialty medicines. The group serves global healthcare markets with a portfolio that spans injectables, branded pharmaceuticals and other treatments aimed at a broad base of patients and healthcare providers.
Average Trading Volume: 1,144,269
Technical Sentiment Signal: Sell
Current Market Cap: £2.81B
For a thorough assessment of HIK stock, go to TipRanks’ Stock Analysis page.